Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure

• Status: Completed
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase III, randomized, prospective clinical study, aiming to compare the analgesic effects of celecoxib, parecoxib, and oxycodone in patients with inoperable hepatic carcinoma undergoing TACE procedure in postoperative pain control.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Celecoxib; Oxycodone; Parecoxib

Criteria

Inclusion Criteria:

• Patients included in the study were classified with stage B or C according to the Barcelona Clinic Liver Cancer (BCLC) staging classification.

• Patients were recommended to receive TACE therapy for HCC.

Exclusion Criteria:

• hypersensitive to celecoxib, parecoxib, and oxycodone

• a history of serious allergic reactions to medicines

• stomach ulcers or bleeding in the stomach or gut

• allergic-type reactions such as bronchospasm, cold-like symptoms, polyps in the nose, swelling of the face or hives after taking aspirin or NSAIDs, including other COX-2 inhibitors

• severe liver disease

• inflammatory bowel disease

• heart failure, ischaemic heart disease, peripheral artery disease, or cerebrovascular disease

• women during the last three months of pregnancy or to breast-feeding women

• after coronary surgery